Anixa Biosciences, Inc.

NASDAQ:ANIX

Biotechnology

Healthcare
$2.71 +3.72%

+$0.10 today

Market cap
$94.21M
Beta
0.60
P/E (TTM)
-9.3
EPS (TTM)
-$0.30
52W Low $2.32High $5.46

Volume 0.29M

Average 0.12M

ANIX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Anixa Biosciences, Inc.NASDAQ: ANIX

Weighted Avg Shares · Q2 FY2026 · quarter ended Apr 2026

Weighted avg shares grows in line with its trailing trend

Q2 FY2026 weighted avg shares of 33.59M shares rose 4.3% year over year, ahead of the +2.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.1% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.3% holds above the trailing-twelve-month pace of +2.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
33.59M+1.1% QoQ
Last fiscal yearOct 2025
32.45M+1.7% YoY
LTMApr 2026
32.94M+2.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.3%——
1 year+1.7%——
3-year CAGR+2.2%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
32.45M USD
Year-over-year change
+1.7%
4-year CAGR
+3.2%

Weighted Avg Shares vs competitors

How ANIX compares with its peers on the latest reported figures

  • ANIX's LTM Apr 2026 weighted avg shares of 32.94M shares is the 9th highest of the 10 companies compared; the peer median is 56.4M shares.
  • Its year-over-year change of +2.7% is the 8th highest of 10, against a peer median of +20.6%.
  • Over three fiscal years its annual growth of +2.2% compares with a peer median of +17.0%.
ANIX Competitors Peer median
Weighted Avg Shares for ANIX and competitors
Company Period LTM YoY 3-year CAGR
IRDOpus Genetics, Inc.LTM Mar 2026406.29M +1283.9%+214.9%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026312.72M +1040.7%+186.8%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 202661.23M +1.8%+14.3%
SEERSeer, Inc.LTM Mar 202656.96M -7.5%-2.7%
SPROSpero Therapeutics, Inc.LTM Mar 202656.4M +3.7%+14.2%
HURATuHURA Biosciences, Inc.LTM Mar 202650.79M +127.0%+911.7%
ENTXEntera Bio Ltd.LTM Mar 202646.97M +20.6%+17.0%
AGENAgenus Inc.LTM Mar 202633.32M +48.8%+28.3%
ANIXAnixa Biosciences, Inc.LTM Apr 202632.94M +2.7%+2.2%
ACTUActuate Therapeutics IncLTM Mar 202621.96M +12.5%+11.8%
Peer median (excluding ANIX) 56.4M+20.6%+17.0%

Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Revenue512K0210K00
Cost of Revenue385K0161K036K
Gross Profit127K049K0(36K)
Gross Margin24.8%—23.3%——
Research & Development6.19M6.7M4.77M6.4M5.07M
Selling, General & Admin7.07M7.17M6.29M7.44M6.63M
Operating Expenses13.26M13.88M11.06M13.83M11.67M
Depreciation & Amortization59.86K42K46K37K36K
EBITDA(13.08M)(13.73M)(9.88M)(12.66M)(10.99M)
EBITDA Margin-2554.9%—-4706.7%——
Operating Income(13.14M)(13.88M)(11.01M)(13.83M)(11.7M)
Operating Margin-2565.6%—-5243.3%——
Interest Income2.32K104K1.08M1.13M673K
Interest Expense322104K000
Other Income / Expenses7.77K104K1.08M1.13M673K
Income Before Tax(13.13M)(13.77M)(9.93M)(12.7M)(11.03M)
Pre-Tax Margin-2564.0%—-4728.6%——
Income Tax Expense00000
Net Income(12.95M)(13.6M)(9.81M)(12.55M)(10.93M)
Net Margin-2528.6%—-4671.9%——
EPS (Basic)(0.45)(0.45)(0.32)(0.39)(0.34)
EPS (Diluted)(0.45)(0.45)(0.32)(0.39)(0.34)
Weighted Avg Shares28.58M30.37M30.98M31.9M32.45M
Weighted Avg Shares (Diluted)28.58M30.37M30.98M31.9M32.45M

Anixa Biosciences, Inc.

NASDAQ:ANIX

Intrinsic Alpha fair value

Locked

Current Price

$2.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.